Cybin Inc

"I took that experience of falling flat on my face with the presentations and got a sales job. So I went from being this awful presenter to forcing myself to present about 10 times a day." In Part 1 of The Biotech Startups Podcast conversation with Cybin Inc CEO Doug Drysdale, a big theme is embracing challenges to drive personal and professional growth. Doug talks about: – Navigating the transition from academia to the corporate world and the unexpected paths that can lead to success – The importance of stepping out of your comfort zone, as demonstrated by Doug's shift from science to sales – Innovative strategies in business, such as leveraging pharmacy relationships to gain market share – The role of mentorship and support in overcoming personal weaknesses and achieving career milestones This episode is packed with valuable insights and real-world lessons from Doug's journey in the biotech industry. Head over to Apple Podcasts or Spotify for this episode and more stories only a biotech exec can tell! #biotechnology #lifesciences #podcast

“The path towards approval and commercialization for our novel therapeutics is coming into focus as we work efficiently to provide improved outcomes for patients and their families.” — #Cybin CEO Doug Drysdale Read more: https://loom.ly/dpQL2kI #researchanddevelopment #psychedelicresearch #clinicalresearch #mentalhealth

We are hiring! VP Regulatory Affairs https://lnkd.in/ePCNyUtj   Do you know a potential future Cybinaut? Send them the link to apply!

“Supported by the BTD from the FDA and positive four-month durability data for our CYB003 program, and the initiation of our Phase 2 study of CYB004, we are progressing quickly to potentially change the treatment paradigm for MDD and GAD and bring to market innovative treatment options for patients in need.” — #Cybin CEO Doug Drysdale Learn More: https://shorturl.at/vA3oR

Clinical site selection is complete for #Cybin’s Phase 3 multinational study of #CYB003 — our deuterated psilocybin analogue for the adjunctive treatment of Major Depressive Disorder #MDD — which is expected to begin soon. Over 30 clinical sites have been selected across the United States and Europe. Cybin has evolved into a mature, late-stage company with critical milestones on the near-term horizon. Learn more: https://shorturl.at/vA3oR

We are hiring! Director Clinical Operations https://lnkd.in/gXWN4xbX Project Manager Clinical Operations https://lnkd.in/ghZkAS_n Do you know a potential future Cybinaut? Send them the link to apply!

Further to recent industry discussion, #Cybin plans to implement multiple measures to mitigate the risk of #FunctionalUnblinding in our Phase 3 pivotal trials of #CYB003 for the adjunctive treatment of Major Depressive Disorder #MDD. Read our below and learn more at https://lnkd.in/g2evfR-g #MentalHealth #Biotechnology

“Following our productive Type B meeting, we continue to expect to commence our Phase 3 pivotal program in late summer,” said Doug Drysdale, Chief Executive Officer of Cybin. “Having selected 30 clinical sites across the United States and Europe, we are eager to initiate this next phase of clinical development and to build on the positive impact of CYB003 to date." Read more: https://loom.ly/4r6Nng0 #Breathrough #Neuropsychiatiry #Biotechnology #MentalHealthInnovation

We are #hiring Clinical Monitoring Manager (2 Roles Available) To apply please visit: https://lnkd.in/g3nXrNVB

"The path towards approval and commercialization for our novel therapeutics is coming into focus as we work efficiently to provide improved outcomes for patients and their families,” said #Cybin CEO Doug Drysdale Read our Q1 FY2025 financial results and recent business highlights: https://loom.ly/4r6Nng0 #MentalHealth #Biotechnology